E6(R3): Beyond Compliance in Vendor Oversight

ICH E6(R3), Vendor Governance, KPI Monitoring, and AI-Driven Operational Oversight

ICH E6(R3) is reshaping how sponsors approach vendor oversight.

Oversight can no longer rely on periodic reviews, disconnected spreadsheets, or static governance presentations. Organizations are increasingly expected to demonstrate continuous, risk-based, and traceable oversight across outsourced clinical activities.

As outsourcing models become increasingly complex, sponsors need more centralized, traceable, and continuous oversight across vendors, CROs, and outsourced clinical activities.

In Clinical Maestro’s webinar, “E6(R3): Beyond Compliance in Vendor Oversight,” industry experts discussed the operational realities behind these evolving expectations and how organizations are working to improve governance visibility, inspection readiness, and vendor performance management.

Key Discussion Topics

• continuous, risk-based vendor oversight
• governance visibility and operational traceability
• KPI monitoring and performance trending
• escalation and issue management
• vendor qualification and category management
• inspection readiness under ICH E6(R3)
• AI-driven operational intelligence and reporting

Why Vendor Oversight Is Becoming More Complex

As outsourcing models continue to expand across pharma and biotech, sponsors increasingly rely on CROs, labs, imaging vendors, specialty providers, and global supplier ecosystems.

At the same time, governance data often remains fragmented across spreadsheets, emails, PowerPoint presentations, disconnected systems, and department-specific workflows.

This creates major challenges around operational visibility, traceability, inspection readiness, escalation management, KPI monitoring, and vendor performance oversight.

How AI Can Support Continuous Oversight

The webinar explored how AI and connected governance workflows can help organizations move from reactive oversight toward continuous operational intelligence.

Examples discussed included centralized vendor visibility, KPI dashboards and trend analysis, governance event tracking, escalation and issue management, AI-generated insight reports, and inspection-ready reporting workflows.

The discussion emphasized that effective oversight requires more than static documentation. It requires connected operational data, continuous monitoring, and traceable governance processes.

Key Takeaways

• ICH E6(R3) is accelerating the shift toward continuous oversight
• Sponsors need more active and traceable governance models
• KPI visibility and performance trending are becoming critical operational capabilities
• Escalation management remains highly fragmented across the industry
• AI can support operational intelligence and inspection readiness
• Vendor oversight is evolving toward operational resilience and continuous governance

Frequently Asked Questions

What is continuous vendor oversight?

Continuous vendor oversight refers to ongoing, risk-based monitoring of vendor performance, governance activities, escalations, KPIs, and operational risks throughout the clinical trial lifecycle.

Why is vendor governance important in clinical trials?

Vendor governance helps sponsors maintain operational quality, inspection readiness, compliance, and visibility across outsourced clinical activities.

What are the biggest challenges in vendor oversight today?

Common challenges include fragmented systems, spreadsheet-based workflows, disconnected escalation management, limited KPI visibility, and lack of centralized governance data.

How can AI improve vendor oversight?

AI can support vendor oversight by automating reporting, analyzing trends, improving governance visibility, supporting inspection readiness, and generating operational insights from connected operational data.

What does ICH E6(R3) change for sponsors?

ICH E6(R3) increases expectations for continuous, risk-based, and traceable oversight of vendors, suppliers, and outsourced clinical activities.

Watch the Webinar Recording

Watch the full webinar recording to explore how industry leaders are approaching continuous vendor oversight, governance visibility, KPI monitoring, operational intelligence, and inspection readiness under ICH E6(R3).

Speakers:

• Anca Copaescu — Founder, Clinical Maestro
• Sameer Tandon — Bristol Myers Squibb
• Andrei Antonescu — Head of Product, Clinical Maestro